PASSconviction 3published 2026-09-11

HBCP — Home Bancorp, Inc. · 2026-09-11 · Verdict: PASS · Conviction 3

Price $69.47 (screen row, priced 2026-09-11) · Mkt cap $547M · P/E 11.7x TTM · P/TBV 1.48x · ROTCE 12.9% · TBVPS growth +13.2% · ADV $5.0M Sources read: 10-K 2026-03-06 (Items 1, 1A, 7), 10-Q 2026-08-03 (Item 2), DEF 14A 2026-04-02, 8-Ks 2026-07-20 (Q2 results and investor deck), 2026-07-06, 2026-06-26, 2026-04-20, Form 4s (trailing 12m).

Desk stats

1. What the business actually does

Home Bancorp is the holding company for Home Bank, N.A., a 118-year-old community bank headquartered in Lafayette, Louisiana, with 43 offices across south Louisiana, Natchez, Mississippi and Houston (10-K 2025, Item 1). Management has deliberately shifted the book toward commercial real estate and commercial and industrial loans "due to their generally higher yields and shorter anticipated lives" (10-K 2025, Item 1). At 30 June 2026 the $2.78B loan book was 44% commercial real estate, 16% commercial and industrial, 12% construction and land, 7% multi-family, 17% residential and home equity (10-Q Q2 2026). Six acquisitions since the 2008 conversion, most recently Texan Bank in Houston in 2022.

2. Why it is mispriced — the edge case

There isn't one. This is a well-run, well-followed community bank with Dimensional and BlackRock each above 5% (DEF 14A 2026). Not a spin-off, not orphaned, no forced sellers. The stock has re-rated from 1.12x tangible book to 1.46x in four quarters (8-K 2026-07-20, Quarterly Financial Highlights) and sits 4% off its 52-week high. The market is not missing anything on the upside.

3. Credit quality, margin and deposits

This is where the case breaks. Criticized loans went $51.6M, $61.6M, $65.8M, $72.6M, $95.8M across the last five quarters, or 1.87% to 3.45% of total loans (8-K 2026-07-20, investor deck). Special mention alone went $1.8M to $26.9M, with commercial real estate special mention up 578% to $20.0M in six months (10-Q Q2 2026). Nonperforming assets are $39.2M, 1.09% of assets, against 0.45% at end-2024 (10-K 2025, Item 7). The headline that nonperforming loans fell to $26.4M in Q2 is not a resolution: foreclosed assets and ORE rose from $1.9M at December 2025 to $12.8M at June 2026 (8-K 2026-07-20, credit tables). The loans moved into foreclosure, not off the books.

Against $95.8M of criticized loans the allowance is $34.0M, 1.22% of loans, essentially unchanged for six straight quarters. Allowance coverage of nonperforming assets has gone 131% to 87% in a year. TTM net charge-offs are 6bp, which is why earnings look untroubled. The President said on 21 July that "while criticized loans increased during the quarter, we do not anticipate any sizable losses" (8-K 2026-07-20). That may prove right. It is a forecast, not a fact, and the stock is priced as if it is a fact.

Funding is genuinely good: NIM 4.24%, loan yield 6.46%, core deposits up 8% annualised, loan-to-deposit 90.6%, uninsured deposits $959.4M or 31% of deposits with public funds fully collateralised (10-Q Q2 2026).

4. Balance sheet and capital allocation

$54.7M subordinated debt and $3.0M FHLB advances against a $1.3B FHLB line (10-K 2025, Item 1). Share count is down from 8.74M in 2019 to 7.87M, 17% retired at an average $35.37 (8-K 2026-07-20, capital page). The pattern is informative: 321,590 shares bought at an average $44.30 in 2025, and 7,052 shares at $61.16 in 2026 through 17 July. Management stopped buying its own stock at these prices. The dividend rose 3% to $0.32, a 19% payout. Directors and officers own 6.2%, the CEO 2.6%, the ESOP 6.3% (DEF 14A 2026). Insider open-market activity over twelve months: zero purchases, 2,550 shares sold for $174,282 (Form 4 summary).

5. Management: said versus did

Bordelon has run this bank for decades and the 8.8% tangible book CAGR since 2019 is real. Two things give pause. On 26 June 2026 the board promoted Chief Risk Officer Darren Guidry to President and he "relinquished the position of Chief Risk Officer" (8-K 2026-06-26); no successor is named in any filing here, and the vacancy coincides with criticized loans rising 32% in that same quarter. And the executive who oversaw the underwriting of this book is now the one guaranteeing its outcome.

6. Valuation

Framework: P/TBV equals (sustainable ROTCE minus growth) over (cost of equity minus growth), at a 10% cost of equity. - Bear (30%): the $95.8M criticized book seasons at a 20% loss rate, about $19M of charge-offs over two to three years, roughly 4% of tangible common equity; ROTCE settles at 9.5%, growth 4%, multiple 0.92x on $47 tangible book. $43. - Base (45%): 30bp is the right mid-cycle credit cost, ROTCE 11%, growth 4%, multiple 1.17x, plus a year of book accretion. $59. - Bull (25%): "no sizable losses" proves right, loan growth returns to Q2's 7% annualised pace, ROTCE holds 13.5%, growth 5%, multiple 1.70x on $51 of tangible book a year out. $87. Probability-weighted $61, about 12% below $69.47. Reverse DCF: at 1.48x tangible book, a 10% cost of equity and 5% long-run growth, the current price implies a sustainable ROTCE of about 12.4% in perpetuity. The bank posted 12.9% last quarter on a 7bp provision, so the price implies today's under-provisioned return is the permanent return.

7. Catalysts and timeline

Q3 2026 results in late October: the criticized-loan roll and the ORE balance are the two numbers that matter. Appointment of a new Chief Risk Officer. Resumption or continued absence of buybacks.

8. Pre-registered kill criteria (what would make this PASS wrong)

  1. Criticized loans below 2.5% of total loans for two consecutive quarters, with foreclosed assets and ORE back under $5M.
  2. The construction, land and commercial real estate credits now in foreclosure resolve with cumulative net charge-offs under $3M, confirming the collateral marks.
  3. The stock trades back under 1.15x tangible book, roughly $55 on current book.
  4. Insider net open-market buying above $250K, or buybacks resuming above 50,000 shares in a quarter.

9. Verdict and summary

PASS, conviction 3. Home Bancorp is a good bank at a full price, and the two facts sit badly together. Revenue grew 10% in 2025 and 7% last quarter, but all of it is margin: the net interest margin went 3.71% to 4.24% on deposit repricing while loans grew half a percent year over year, and that deposit tailwind is largely spent. Meanwhile criticized loans nearly doubled in twelve months, 1.87% to 3.45% of the book, special mention went from $1.8M to $26.9M, and foreclosed real estate went from $1.9M to $12.8M in six months, so last quarter's improvement in nonperforming loans was migration into foreclosure rather than repayment. The allowance has sat at 1.21-1.23% of loans throughout and the trailing provision is 7bp, which is why reported earnings look fine; put a 30bp mid-cycle provision through and normalised after-tax profit is about $38.5M, so you pay 14.2x normalised earnings and 1.48x tangible book for a normalised return on tangible equity nearer 10.5% than the reported 12.9%. At that price the market already treats the new President's "we do not anticipate any sizable losses" as settled. Management's own behaviour argues otherwise: they bought 321,590 shares at $44.30 in 2025 and 7,052 in 2026, insiders have made no open-market purchases in twelve months, and the Chief Risk Officer seat was vacated in the same quarter criticized loans rose 32%. Probability-weighted value is around $61 against $69.47. Worth revisiting at 1.15x tangible book, or after two quarters of criticized loans actually falling.

Research for discussion, not investment advice. Positions and sizing are the reader's decision.

Source markdown: 2026-09-11_HBCP.md · how these notes are built · every verdict tracked since publication.

Research and education only. Nothing here is investment advice or a recommendation to buy or sell any security. No price targets are recommendations; positions and sizing are the reader's decision. Past performance does not predict future results.